Actively Recruiting
Study of Oral Trametinib for Treating RasMAPK Pathway Driven Vascular Anomalies in Children and Young Adults
Led by Children's Hospital of Philadelphia · Updated on 2026-10-19
45
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of the drug Trametinib in patients with vascular anomalies caused by abnormalities in the RasMAPK pathway. Trametinib is approved for treating metastatic melanoma but is being studied here for its effects on vascular anomalies. The study focuses on participants aged from 2 months to 30 years with these specific vascular anomalies requiring medical treatment. Participants will receive oral Trametinib daily in continuous 28-day cycles at a dose of 0.025 mgkgday, with a maximum dose of 2 mg. Dose reductions are allowed if needed due to side effects but only if the participant still shows clinical benefit. Treatment will last at least 2 years and can continue up to 3 years based on response. The study includes up to 16 clinic visits during which participants will take the medication, have pictures taken, complete drug diaries, and optionally provide blood samples for biomarker testing. During the study, participants will be evaluated using radiologic assessments, patient-reported outcome questionnaires, and clinical benefit assessments at multiple time points including after 6, 12, and 24 cycles each cycle is 28 days. Researchers will monitor changes in lesion size, quality of life, and response to treatment. Safety will be assessed through laboratory tests and clinical observations. Participation involves regular visits, questionnaires, and adherence to medication for up to 3 years total.
CONDITIONS
Brief Title
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
Research Team
C
CVAP Research Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here